Ensysce Biosciences (NASDAQ:ENSC) Issues Earnings Results, Beats Expectations By $0.24 EPS

Ensysce Biosciences (NASDAQ:ENSC) posted its quarterly earnings results on Monday. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.24, FiscalAI reports. The business had revenue of $1.88 million for the quarter, compared to the consensus estimate of $0.50 million. Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%.

Ensysce Biosciences Price Performance

Shares of NASDAQ ENSC opened at $0.51 on Tuesday. The stock has a market capitalization of $1.87 million, a P/E ratio of -0.08 and a beta of 1.14. The company has a 50-day moving average price of $0.56 and a 200-day moving average price of $1.34. Ensysce Biosciences has a 1 year low of $0.31 and a 1 year high of $4.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Ensysce Biosciences

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Ensysce Biosciences during the 3rd quarter valued at about $34,000. Citadel Advisors LLC purchased a new stake in shares of Ensysce Biosciences in the third quarter worth approximately $34,000. DRW Securities LLC lifted its holdings in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.